New research confirms benefits of chondroitin for osteoarthritis
27 February 2015 - The Australian Self Medication Industry (ASMI) today welcomed new research that confirmed the benefits of chondroitin sulphate for osteoarthritis.
A Cochrane Review of 9,110 people across 43 randomised
controlled studies revealed that chondroitin sulphate (alone or in
combination with glucosamine) was better than placebo in improving
pain in participants with osteoarthritis in short term studies. The
review also revealed a slight slowing of the narrowing of the joint
space on X-rays of the affected joint, and improved quality of
life, using an index which included measures of pain, function and
disability. Chondroitin sulphate was found to have a lower risk of
adverse events compared with control.
ASMI Regulatory and Scientific Affairs Director, Mr Steve Scarff, said: "ASMI welcomes new research that adds to the body of knowledge on complementary medicines.
"Evidence about the efficacy and safety of complementary
medicines is important so that consumers can be confident of the
claims made about them.
"This Cochrane Review is a great way of making sense of a large number of studies, helping consumers and other stakeholders to understand the benefits of chondroitin sulphate in osteoarthritis," Mr Scarff added.
About ASMI: The Australian Self Medication Industry (ASMI) is the peak body representing sponsors of non-prescription medicines - over-the-counter (OTC) and complementary medicines (CM). ASMI members make up 85 per cent of the $4bn Non-Prescription Medicines market. Membership totals 50 companies and ASMI members employ approximately 18,000 people with exports estimated at $1.2 billion annually. ASMI's mission is to advance consumer health through responsible self-care. This means driving a viable and responsible industry and empowering the consumer with evidence-based products and information with the aim of improving health and wellbeing. To find out more about ASMI or how to become an ASMI member, please visit (www.asmi.com.au).
For more information or to arrange a media interview, please
Communications Manager, Australian Self Medication Industry (ASMI)
M:0408 256 381 E: email@example.com